Vertex Pharma Stock - Analyst consensus and technical picture on Nasdaq
18.06.2026 - 19:57:29 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 17:50 UTC. Details in the imprint.
Vertex Pharma (US92532F1003) develops and markets therapies for serious diseases and its stock is a heavyweight on Nasdaq’s biotech bench. With no fresh corporate news in the past 24 hours, today’s focus is on analyst consensus and the current chart picture for the shares.
All news and analysis on Vertex Pharma stock
Additional market data, historical news and regulatory filings on Vertex Pharma stock are available in the dedicated topic overview.
What analysts currently expect
According to data compiled by several market platforms, Wall Street’s stance on Vertex Pharma stock is broadly constructive, with an overall "Buy" rating dominating the distribution of recommendations. A consensus one-year price target around $550 per share implies meaningful upside versus recent levels.
One data provider cites an average target of about $549.86, underscoring that most covering houses still see valuation support despite the stock’s strong multi-year run. Against this backdrop, the consensus embeds expectations of continued earnings growth from the cystic-fibrosis and pipeline franchises.
Chart levels and volatility on Thursday
On Wednesday, Vertex Pharma shares closed around $459 on Nasdaq, valuing the company at roughly $116.5 billion. The stock edged higher by just over 1% in that session, a move in line with broader strength in large-cap growth names.
Based on recent quote data, Vertex Pharma shares currently trade well above many long-term moving averages, reflecting a robust longer-term uptrend. Shorter-term swings remain noticeable, but the overall technical picture stays constructive while the price holds in the upper part of its 52-week range.
How the company makes money
Vertex Pharma generates the bulk of its revenue from precision medicines for cystic fibrosis, led by its Trikafta/Kaftrio combination therapy, which treats patients with specific CFTR gene mutations. The group also invests heavily in research on gene-editing and other therapies targeting sickle cell disease and additional serious conditions.
Where the stock trades today
The shares of Vertex Pharma (US92532F1003) trade on Nasdaq at $459.17 as of 06/17/2026, 16:00 ET.
Key facts on Vertex Pharma stock
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- WKN: 882807
- Ticker: VRTX
- Venue: Nasdaq
- Price (as of 06/17/2026, 16:00 ET): 459.17 USD
- Market cap: 116,539,833,324 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
